Top Stock Losers: Healthcare, Biotech, and Leveraged ETFs

Font: Financial Modeling Prep  • Jun 16, 2026

Today's Top Stock Losers: Healthcare Names and Leveraged ETF Volatility Lead Declines

• Healthcare and medical technology stocks were among the day's sharpest decliners.
• Veraxa Biotech, SANUWAVE Health, Cuprina Holdings, and Regentis Biomaterials saw steep losses.
• The GraniteShares 2x Long MRVL Daily ETF amplified Marvell Technology's decline through leverage.

Today's market featured several sharp declines across healthcare, biotechnology, medical technology, and leveraged ETF products. Top losers included Veraxa Biotech AG (NASDAQ: VRXA), SANUWAVE Health (NASDAQ: SNWV), Cuprina Holdings (NASDAQ: CUPR), Regentis Biomaterials (NYSE American: RGNT), and the GraniteShares 2x Long MRVL Daily ETF (NASDAQ: MVLL).

Veraxa Biotech AG led the decline. Shares fell $11.76, or 55.32%, to $9.46. The company recently began trading on the Nasdaq Capital Market after completing its business combination with Voyager Acquisition Corp. Veraxa is developing next-generation cancer therapies, including bispecific T-cell engagers and antibody-drug conjugates. The sharp decline appears tied to post-listing volatility rather than a clearly identified same-day operational announcement.

SANUWAVE Health shares dropped $6.16, or 41.99%, to $8.51. The company provides FDA-approved wound-care technology through its Ultramist platform. The decline followed concerns around updated revenue expectations and softer Ultramist capital equipment sales, even as consumables demand remained an important part of the business.

Cuprina Holdings shares also fell sharply, declining $3.25, or 38.64%, to $5.27. The company recently announced U.S. FDA 510(k) clearance for MEDIFLY Maggots, its Lucilia cuprina maggot debridement therapy product. Despite the regulatory milestone, the stock remained highly volatile after its recent rally.

Regentis Biomaterials declined $3.25, or 34.57%, to $6.10. The regenerative medicine company recently highlighted plans to advance the European commercial rollout of GelrinC, its CE Mark-approved implant for knee cartilage lesions. The selloff reflects continued volatility in small-cap medical technology stocks, even when companies report commercialization progress.

The GraniteShares 2x Long MRVL Daily ETF fell $38.44, or 19.75%, to $155.79. The fund seeks to deliver two times the daily performance of Marvell Technology (NASDAQ: MRVL). Because Marvell shares declined sharply, MVLL magnified that move through its leveraged structure.

In summary, the day's top losers were driven by a mix of post-listing volatility, revised revenue expectations, profit-taking after regulatory news, small-cap healthcare weakness, and leveraged ETF exposure. Veraxa, SANUWAVE, Cuprina, and Regentis reflected pressure across speculative healthcare names, while MVLL showed how leveraged products can amplify downside moves in the underlying stock.